Latest Options News

Australian Mines has reaffirmed strong economics for its Flemington Scandium Project, highlighting a robust 28-year mine life and significant leverage to scandium price scenarios.

WA Kaolin is seeking up to A$34.9 million through a fully underwritten entitlement offer aimed at restructuring its balance sheet, reducing shareholder loans, and funding operational improvements at its Wickepin kaolin project.

Jindalee Lithium has locked in a strongly supported A$11 million capital raise through a placement and entitlement offer to fund its McDermitt Lithium Project and the proposed NASDAQ listing of US Elemental Inc.

Core Lithium has completed the second tranche of a A$120 million equity raise, securing A$67 million and shareholder approval for convertible notes, positioning the Finniss Lithium Project for continued development.

Taiton Resources has finished drilling a single 810m diamond hole at its Yogi prospect within the Highway Project, South Australia, with assay results due in June.

Aquirian Limited has secured $8 million through a strongly supported placement to accelerate growth of its Drillforce business and support a major $48 million contract at the Lord Byron mine.

Classic Minerals faces a full trial in its legal dispute over Forrestania tenements but retains 80% gold rights and asserts claims to full ownership, continuing exploration plans amid uncertainty.

Amaero Ltd has sent out its Scheme Booklet for the upcoming June 5, 2026 meetings where shareholders will vote on the company’s re-domiciliation to the US and approve new incentive options.

Chatham Rock Phosphate has secured a definitive financing agreement with Wetstone Global that doubles an existing loan to USD 300,000 and converts it into a 30% equity stake, granting Wetstone majority board control and potential for up to 70% ownership upon project milestones.

Pengana International Equities (ASX:PIA) unveils a comprehensive capital management plan offering shareholders an equal-access off-market buy-back at after-tax NTA, a fully franked special dividend, and appoints Antipodes Global Investment Management to steer its portfolio.

Amplia Therapeutics and ANZGOG have initiated a clinical trial to test narmafotinib combined with chemotherapy in ovarian cancer patients unresponsive to platinum-based treatment, aiming to improve surgical outcomes and explore biomarker insights.

Australian Unity Office Fund has called an extraordinary meeting to secure approval for selling its final property, delisting from the ASX, and winding up the fund, with directors unanimously recommending the proposal.